Endo to present nine XIAFLEX studies in Peyronie’s disease at SMSNA Annual Meeting 2025

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that nine presentations related to Peyronie’s disease, or PD, and XIAFLEX^® (collagenase clostridium histolyticum, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place October 9-12, 2025.

“I’m proud to be part of a medical community taking a closer look at Peyronie’s disease, which is common but often overlooked,” said Jesse N. Mills, MD, urologist and presenting author of three of the presentations. “I believe that providers at SMSNA will be better equipped to support their patients with educational information that includes these latest data and insights.”

The nine new and modified Endo-sponsored and Endo-supported presentations are below:

Sponsored by Endo:

• Understanding Peyronie’s Disease Through a Women’s Health Lens: A Survey of Women’s Sexual Health Provider Practices and Awareness
  • Authors: Irwin Goldstein, MD; Sue W. Goldstein, CSE, CCRC, IF; Rose Hartzell-Cushanick, PhD, EdS; Tami Rowen, MD; Sameena Rahman, MD; Becky Lynn, MD; Alyse Kelly-Jones, MD; David Hurley, MD; Nicole Tay, MS; Sheryl Kingsberg, PhD
• Treatment Patterns for Peyronie’s Disease (PD): Results of a Survey of Men’s Healthcare Providers (HCPs)
  • Authors: James A. Kashanian, MD; Kristen Gumpf, PA-C; Tina Rezakhani, PharmD; Sherry Chen, MS; David Hurley, MD; Jesse N. Mills, MD
• Collagenase Clostridium Histolyticum for Ventral Curvature of the Penis Due to Peyronie’s Disease: Updated Results From a Noninterventional, Retrospective, Multicenter Study
  • Authors: Matthew J. Ziegelmann, MD; Billy H. Cordon, MD; Majdee M. Islam, MD; Alexander J. Tatem, MD; Richard C. Bennett, MD; Faysal A. Yafi, MD, FRCSC; Petar Bajic, MD; Nelson E. Bennett, Jr., MD; Helen L. Bernie, DO, MPH; Marcelo Mass-Lindenbaum, MD; Muhammed A. M. Hammad, MBBCh, MS; Kristen Gumpf, PA-C; James Tursi, MD; David Hurley, MD; Jeffrey Andrews, MS; Tina Rezakhani, PharmD, MBA; Marian Ayad, PharmD, BCPS; Mohit Khera, MD, MBA, MPH; Bruce R. Kava, MD; Jesse N. Mills, MD
• Peyronie’s Disease Patients With Pain: A Post Hoc Analysis of the IMPRESS I/II Studies
  • Authors: Jesse N. Mills, MD; Gregory A. Broderick, MD; David H. Hurley, MD; James P. Tursi, MD; Marian Ayad, PharmD, BCPS; Tina Rezakhani, PharmD, MBA; Sajel Patel, PharmD; Qinfang Xiang, PhD; Jeffrey Andrews, MS; Landon W. Trost, MD

Investigator-Initiated Research:

• Clinical Outcomes in Peyronie’s Disease: Impact of Curvature Severity and Disease Phase on Symptom Resolution and Treatment Response
  • Authors: Gal Saffati, MD; Beatriz Hernandez, MD; Aidan Boyne, BS; Geneva Pantoja, BS; Alex Beck, BS; David E. Hinojosa-Gonzalez, MD; Mohit Khera, MD, MBA, MPH
• Advanced Practice Provider Recall of Men’s Health Content in Academic Program Curricula
  • Authors: Susanne Quallich, PhD, ANP-BC, NP-C, CUNP, FAUNA, FAANP; Robert Calimente, MS; Kenneth Mitchell, MPAS, PA-C
• Qualitative Analysis of the Impact of Peyronie’s Disease On Female Partners
  • Authors: Stacy Loeb, MD, MSc; Jasmine Saunders, MPH; Evangelia Pitsoulakis, MPH; Mariana Rangel Camacho, MPH; Adrian Rivera, MPH; Nataliya Byrne, MPH; Tatiana Sanchez Nolasco, MPH; Hossein Sadeghi Nejad, MD; Bobby Najari, MD; Chris Nelson, MPH; John P. Mulhall, MD
• Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie’s Disease: A Randomized Trial – 3 Year Outcomes
  • Authors: Benjamin Green, BA; Ashley Flores, MBA; Jacob Warner, BS; Tobias Kohler, MD; Sevann Helo, MD; Landon Trost, MD
• Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie’s Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
  • Authors: Bryce Palmer, BS; Joshua Savage, PA-C; Klinton Brearton, CNP; Riley Warner, PA-C; Matthew Ziegelmann, MD; Sevann Helo, MD; Tobias Kohler,